September 18, 2024
Invion (ASX:IVX): a safer path forward in prostate cancer treatment with INV043
Invion’s groundbreaking INV043 therapy offers a promising, safer alternative for prostate cancer treatment, with early trials showing strong safety and encouraging efficacy results.